Annovis Bio, Inc. (ANVS): Due to a typographical error in the Company’s proxy statement for its annual meeting of stockholders held on June 17, 2026, the Company is filing this…
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events Due to a typographical error in the Company’s proxy statement for its annual meeting of stockholders held on June 17, 2026, the Company is filing this Current Report on Form 8-K to correct the disclosure of audit fees. The corrected fees are as follows: Fee
How this was made
The 30-second read
Why it matters
The filing provides a factual update with no new strategic or financial guidance; market reaction is expected to be flat.
Market read
Routine compliance filing with negligible trading relevance.
What to watch
The correction does not alter any upcoming clinical or financing milestones.
Background
Annovis Bio filed a Form 8‑K to correct audit‑fee disclosures for its 2024 and 2025 fiscal years after a typographical error in the proxy statement.
Ticker impact
Form 8‑K corrects previously misstated audit fees for 2024‑2025, disclosing $415k and $375k audit fees respectively.
negligible impact as the fee amounts are modest and already anticipated by the market
Audit‑fee adjustments are routine and materiality is low for a micro‑cap biotech; no new business or financial outlook is changed.
Market effects
none
none
none
Counterpoint
Even minor filing corrections can signal tighter compliance focus, but no material effect is expected.
Key entities
- companyAnnovis Bio, Inc.
US‑listed biotech (ticker ANVS) reporting corrected audit fees.
